✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Written by Sophie Chen. Reviewed by Morgan Ellis, MSc Endocrinology · Last updated:
AICAR is the research compound most often described as a pharmacological “exercise in a vial” — a small molecule that switches on the same cellular energy machinery your body activates during a hard workout. Unlike most of the compounds discussed alongside it, AICAR is not a peptide. It is a nucleoside analogue (chemical name 5-Aminoimidazole-4-carboxamide ribonucleotide; the drug-development name is Acadesine, also written AICA riboside), and it works by directly waking up an enzyme called AMP-activated protein kinase — the cell’s master fuel gauge.
This guide explains exactly what AICAR is at the molecular level, how its conversion to ZMP makes it a genuine AMPK activator, what the published research (including the landmark 2008 endurance study) actually showed, what dosing context appears in the literature, the real AICAR side effects you should know about, and the important fact that AICAR sits on the WADA Prohibited List. Everything here is framed for research understanding — AICAR has no approved human therapeutic use.
Key Takeaways
- What it is: AICAR is a small-molecule nucleoside analogue (drug name Acadesine / AICA riboside) — not a peptide. It is supplied as a research-grade laboratory reagent.
- Mechanism: Inside the cell, AICAR is phosphorylated to ZMP, an AMP-mimic that directly activates AMP-activated protein kinase (AMPK) — making AICAR a direct AMPK activator and the original “exercise mimetic”.
- What AMPK does: Boosts insulin-independent glucose uptake (GLUT4 translocation), drives fatty acid oxidation, and switches on mitochondrial biogenesis genes.
- Landmark study: Narkar et al. (Cell, 2008) reported that AICAR increased running endurance in sedentary mice, popularising the “exercise mimetic” label.
- Clinical history: Acadesine was studied as a cardioprotective agent during coronary bypass (CABG) surgery; it never reached approval for any indication.
- Banned in sport: AICAR is on the WADA Prohibited List as a metabolic modulator (class S4). Athletes subject to anti-doping testing must treat it as prohibited at all times.
- Regulatory status: AICAR is not a licensed medicine in any major jurisdiction and has no approved human therapeutic use. Research only.
Important framing: Throughout this guide, “research” refers to bench, animal, or human-subject investigations conducted under appropriate ethical and regulatory oversight. AICAR is offered as a research-grade laboratory reagent (HPLC-verified purity; COA-keyed lots) — not as a personal-use therapeutic, performance enhancer, or weight-loss medication.
What Is AICAR?
The molecule is worth defining carefully because it is constantly grouped with research peptides in fat-loss and longevity discussions, yet it belongs to a completely different chemical class. Peptides are short chains of amino acids; it is a ribonucleoside — a nitrogenous base attached to a ribose sugar — structurally related to the building blocks of RNA and to the natural intermediate produced during purine biosynthesis. That distinction matters for stability, handling, and how it is studied.
It occurs naturally as a metabolic intermediate in every cell. Researchers became interested in administering this compound exogenously because, once it enters a cell and is phosphorylated, it mimics a low-energy signal without the cell actually being depleted. In other words, it can fool the cell into behaving as though it has just done physical work.
From cardioprotection to “exercise mimetic”
The compound’s earliest serious clinical interest was cardiovascular. Under the name Acadesine, it was investigated in the 1990s as a cardioprotective agent given around the time of coronary artery bypass graft (CABG) surgery, with the rationale that boosting adenosine availability and modulating cellular energy stress might protect heart tissue during ischaemia. Large surgical trials were conducted, but Acadesine never secured regulatory approval for that or any other indication. Its scientific identity shifted dramatically in 2008 when a metabolic study reframed it as an “exercise mimetic,” and that label has dominated the research conversation ever since.
How Does AICAR Work? (AMPK Activation)
The mechanism is unusually clean and well-defined, which is part of why it became such a useful research tool. The chain of events runs as follows.
First, the compound is transported into the cell, where the enzyme adenosine kinase phosphorylates it into ZMP (AICAR monophosphate). ZMP is structurally similar to AMP, the molecule that accumulates when cellular energy (ATP) runs low. Because the cell reads a high AMP-to-ATP ratio as “energy is scarce,” ZMP directly tricks the system: it binds and activates AMP-activated protein kinase — AMPK — without the ATP actually being consumed.
Once AMPK switches on, it acts as the cell’s energy-restoring master switch. It increases glucose uptake by promoting GLUT4 transporter translocation to the cell membrane (notably without needing insulin), it ramps up fatty acid oxidation by inhibiting acetyl-CoA carboxylase and lifting the brake on fat burning, and it switches on the transcriptional programme for mitochondrial biogenesis. The net effect resembles the metabolic state of muscle during and after exercise — hence the term exercise mimetic.
Research Spotlight: The 2008 “exercise in a pill” study
The work that put AICAR on the map was Narkar and colleagues, “AMPK and PPARδ agonists are exercise mimetics,” published in Cell in 2008. The team reported that giving AICAR to sedentary mice — animals that had not trained — increased their running endurance compared with untreated controls, and that the effect involved AMPK-driven shifts in muscle gene expression toward an oxidative, fat-burning profile. The finding generated worldwide “exercise in a pill” headlines. It is essential to read it as a controlled rodent experiment, not as proof of a human performance drug.
Infographic text: AICAR enters the cell, is phosphorylated to ZMP (an AMP mimic), and ZMP binds and activates AMPK. Activated AMPK turns ON glucose uptake (GLUT4), fatty acid oxidation, and mitochondrial gene expression, while turning OFF energy-storing pathways. The result is a metabolic state resembling exercise.
Key Benefits & Uses of AICAR
The reported AICAR benefits in the research literature follow directly from AMPK activation. Most AICAR benefits cluster around four research domains, and it is critical to frame these as observed effects in experimental models, not as established human outcomes.
Endurance and the exercise-mimetic effect
The signature reported finding is improved endurance capacity. In the 2008 Cell study, sedentary mice given the compound ran measurably longer than controls, an effect attributed to AMPK reprogramming skeletal muscle toward fatigue-resistant, oxidative fibre characteristics. This is the core of the exercise mimetic concept — the compound nudges muscle toward an adaptation normally earned through training.
Fat oxidation and metabolism
Because activated AMPK strongly promotes fatty acid oxidation, the compound has been used as a tool to study fat metabolism. By inhibiting acetyl-CoA carboxylase, AMPK lowers malonyl-CoA, which removes the brake on carnitine palmitoyltransferase-1 and lets fatty acids enter mitochondria to be burned. This is the mechanistic basis for AICAR’s interest in metabolic and obesity research.
Glucose metabolism research
It triggers glucose uptake into muscle independently of insulin, by promoting GLUT4 translocation. That property made the compound a valuable probe in diabetes and insulin-resistance research, because it lets investigators stimulate glucose disposal through a non-insulin pathway and study that route in isolation.
Cardioprotection research
Reflecting its origins as Acadesine, it has been studied for protecting heart and other tissues against ischaemia-reperfusion injury. The hypothesis links AMPK activation and adenosine modulation to improved cellular survival under low-oxygen stress. This remains research-stage; no cardioprotective indication is approved.
Who Is This Guide For?
- Researchers studying AMPK signalling, mitochondrial biogenesis, or insulin-independent glucose uptake who need a well-characterised pharmacological AMPK activator.
- Metabolism and obesity investigators isolating fatty acid oxidation pathways in cell or animal models.
- Procurement officers deciding between AICAR and newer exercise-mimetic chemistries such as SLU-PP-332.
- Athletes and coaches who need to understand, for compliance reasons, why AICAR is prohibited under anti-doping rules — see the WADA note below.
AICAR Side Effects, Safety & AICAR Dosage
Honest framing first: there is no approved human dosing protocol for it, because it is not an approved medicine. What exists is dosing context from animal studies and from the historical Acadesine surgical trials, plus a documented set of side effects observed in those settings.
Documented and theoretical side effects
| Side Effect | Reported Frequency | Severity & Notes |
|---|---|---|
| Elevated uric acid (hyperuricaemia) | Reported in studies | Plausible via purine metabolism; theoretical gout risk in susceptible individuals. |
| Transient blood-pressure / heart-rate changes | Reported (surgical trials) | Linked to adenosine-modulating activity; monitored in CABG settings. |
| Gastrointestinal upset | Variable | Non-specific; reported across animal and early human exposure. |
| Headache / flushing | Reported | Consistent with adenosine-related vasodilation. |
| Theoretical proliferative / metabolic concerns | Unquantified | Long-term human safety data are absent; chronic AMPK activation effects are not established. |
AICAR dosage context (research only)
There is no validated human AICAR dosage. Animal endurance studies, including the 2008 work, used weight-based dosing of the compound on the order of several hundred milligrams per kilogram per day in rodents — a quantity that does not translate to humans and was delivered under controlled laboratory conditions. The historical Acadesine surgical trials used intravenous infusion regimens supervised in hospital. It also has notoriously poor oral bioavailability and a short half-life, which is one reason large quantities were needed in animal protocols. None of this constitutes a human protocol, and no safe self-administration dose has ever been established.
⚠️ WADA Prohibited List
AICAR is explicitly named on the World Anti-Doping Agency (WADA) Prohibited List as a metabolic modulator (class S4, hormone and metabolic modulators), prohibited at all times — in and out of competition. Any athlete subject to anti-doping testing who uses it risks an anti-doping rule violation. This is a settled regulatory fact and applies regardless of route or dose.
What Does the Research Say?
The evidence base is meaningful but almost entirely preclinical or historical-surgical. The table summarises the most-cited work. Read every entry as research context, not a human efficacy claim.
| Study / Programme | Year | Key Finding | Source |
|---|---|---|---|
| Narkar et al., Cell — “exercise mimetics” | 2008 | AICAR increased running endurance in sedentary mice via an AMPK-driven oxidative gene programme. | PMC2706130 |
| Acadesine CABG cardioprotection programme | 1990s | Studied to reduce ischaemic injury around bypass surgery; no regulatory approval achieved. | PubMed (Acadesine) |
| AMPK as a metabolic master switch (mechanistic body of work) | Ongoing | AICAR is widely used as the standard pharmacological AMPK activator in cell and tissue studies. | PubMed (AICAR + AMPK) |
Infographic text: In the 2008 Cell study, untrained mice receiving AICAR ran longer before exhaustion than untreated untrained mice — the result that launched the “exercise mimetic” concept. This was a rodent model; it is not a demonstrated human performance effect.
AICAR vs Alternatives — Comparison Table
It is frequently compared with other compounds that target the same metabolic “exercise” pathways. The table below is for orientation only.
| Compound | Class | Primary Target | Status |
|---|---|---|---|
| AICAR (Acadesine) | Nucleoside analogue | Direct AMPK activation (via ZMP) | Research only; WADA-banned; no approval |
| SLU-PP-332 | Small-molecule ERR agonist | Estrogen-related receptor (ERR), driving mitochondrial / oxidative genes | Research only; newer exercise-mimetic chemistry |
| GW501516 (Cardarine) | Small-molecule PPARδ agonist | PPARδ, driving fatty acid oxidation genes | Research only; WADA-banned; carcinogenicity flagged |
| Metformin | Biguanide medicine | Indirect AMPK activation (via mitochondrial complex I) | Approved diabetes medicine (clinician-directed) |
The key contrast: AICAR activates AMPK directly through ZMP, whereas metformin activates it indirectly. SLU-PP-332 and GW501516 reach overlapping oxidative outcomes through entirely different nuclear receptors, rather than through AMPK at all. For a sister write-up, see SLU-PP-332, another exercise-mimetic compound.
How to Use AICAR — Practical Guidance
There is no approved consumer protocol for AICAR, so this section covers handling considerations for research-grade material rather than dosing instructions. Research-grade material is typically supplied as a lyophilised (freeze-dried) powder. If a research protocol calls for it in solution, reconstitution and storage follow the same general principles as other lyophilised research compounds — our reconstitution math guide walks through the calculations and sterile technique.
When sourcing it for laboratory use, the benchmark is a batch-specific Certificate of Analysis confirming identity and purity by HPLC, with the lot number matching the vial. You can review specifications on the AICAR (Acadesine) product page, and AICAR sits within our broader research compounds and peptides range alongside related metabolic tools. For investigators specifically comparing fat-metabolism compounds, the best peptides for fat loss hub places AICAR in context with the wider landscape.
Two practical realities to plan around: AICAR’s poor oral bioavailability and short half-life mean route of administration heavily affects exposure in any model, and its WADA-prohibited status means it must never be used by competing athletes.
Frequently Asked Questions
What does AICAR do?
AICAR is converted inside cells into ZMP, a molecule that mimics AMP, the cell’s “low energy” signal. ZMP directly activates AMP-activated protein kinase (AMPK), the cellular energy sensor. Activated AMPK then increases glucose uptake, accelerates fatty acid oxidation, and switches on mitochondrial genes — a metabolic profile resembling the effects of exercise. This is why the compound is described as an exercise mimetic and used as a standard AMPK activator in research settings.
Is AICAR safe?
There is no established human safety profile because it is not an approved medicine and was never authorised for any indication. Reported and theoretical concerns include elevated uric acid, cardiovascular and adenosine-related effects, gastrointestinal upset, and unknown long-term consequences of chronic AMPK activation. It should be regarded strictly as a research-grade laboratory reagent, not something with a known safe self-administration dose.
Is AICAR banned in sport?
Yes. AICAR appears on the WADA Prohibited List as a metabolic modulator (class S4), prohibited at all times, both in and out of competition. Any athlete subject to anti-doping testing who uses it risks an anti-doping rule violation. This applies regardless of dose or route of administration, and there is no realistic therapeutic-use exemption pathway that makes recreational performance use acceptable.
AICAR vs SLU-PP-332 — what’s the difference?
Both are small-molecule exercise mimetics, but they hit different targets. It works through ZMP to directly activate AMPK, the cellular energy sensor. SLU-PP-332 instead activates estrogen-related receptors (ERRs), nuclear receptors that switch on mitochondrial and oxidative metabolism genes. They reach overlapping exercise-like outcomes by different routes. See our SLU-PP-332, another exercise-mimetic compound guide for a fuller comparison.
Does AICAR burn fat?
In research models, it strongly promotes fatty acid oxidation because activated AMPK lowers malonyl-CoA and releases the brake on fat entering the mitochondria to be burned. This makes AICAR a useful tool for studying fat metabolism. However, “burns fat” in a rodent or cell model is not the same as a proven human weight-loss effect, and AICAR has no approved use for fat loss in people.
Is AICAR a peptide?
No. This is a common misconception because it is sold alongside research peptides. AICAR is a small-molecule nucleoside analogue — a nitrogenous base on a ribose sugar, chemically related to RNA building blocks — not a chain of amino acids. Its handling, stability, and mechanism differ accordingly, even though it is studied in the same metabolic context as several peptides.
What is Acadesine and is it the same as AICAR?
Yes, Acadesine is simply the drug-development name for the same molecule, also written as AICA riboside. Under the Acadesine name it was studied as a cardioprotective agent around coronary bypass surgery in the 1990s. When the same compound was later reframed as an exercise mimetic in metabolic research, the AICAR name became more common. They refer to the identical chemical entity.
The Bottom Line
AICAR is the original exercise mimetic — a small-molecule AMPK activator that, by converting to ZMP, convinces cells they have just exercised, driving glucose uptake, fatty acid oxidation, and mitochondrial adaptation. The science is genuinely interesting: a landmark 2008 study showed endurance gains in sedentary mice, and AICAR remains the go-to pharmacological AMPK activator in laboratories worldwide. But the honest picture is equally important. AICAR has no approved human therapeutic use, it carries an undefined long-term safety profile, and it is firmly on the WADA Prohibited List for athletes.
For researchers who need a well-characterised AMPK activator with decades of mechanistic literature behind it, the compound is a standard tool. You can review specifications and Certificate-of-Analysis details on the AICAR (Acadesine) product page and explore related metabolic compounds across our research range.
Medical Disclaimer
This article is for educational and research-information purposes only and does not constitute medical advice. AICAR (Acadesine) is a research-grade laboratory reagent with no approved human therapeutic use and is not a licensed medicine. Nothing here should be interpreted as encouragement to self-administer AICAR or any research compound. AICAR is prohibited in sport under the WADA Prohibited List. Always consult a qualified healthcare professional before making any decision related to your health, and comply with all applicable laws and anti-doping regulations.
Written by Sophie Chen. Medically reviewed by the MedsBase Editorial Team in line with our editorial policy. Last updated 24 May 2026.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.